Phaseline

Companies › PharmaEssentia

PharmaEssentia: clinical trials, targets and expected readouts

1 active drug program in 10 registered trials: 4 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ropeginterferon Alfa-2B (P1101)
Interferon alpha/beta receptor positive modulator
IFNAR1, IFNAR2Phase 3Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) …Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06770842Ropeginterferon Alfa-2B (P1101)Phase 2Primary Myelofibrosis (PMF)OncologyDec 2026
NCT05482971Ropeginterferon Alfa-2B (P1101)Phase 2Essential ThrombocythemiaOncologyMar 2027
NCT05485948Ropeginterferon Alfa-2B (P1101)Phase 2Polycythemia VeraOncologyJul 2027
NCT05481151Ropeginterferon Alfa-2B (P1101)Phase 3Polycythemia VeraOncologyJul 2027
NCT06468033Ropeginterferon Alfa-2B (P1101)Phase 3Primary MyelofibrosisOncologyNov 2027
NCT07047885Ropeginterferon Alfa-2B (P1101)Phase 1Cutaneous T Cell LymphomaOncologyJun 2028
NCT07646821Ropeginterferon Alfa-2B (P1101)Phase 1RopeginterferonOncologyDec 2028
NCT07521046Ropeginterferon Alfa-2B (P1101)Phase 1MyelofibrosisOncologyAug 2029
NCT04285086Ropeginterferon Alfa-2B (P1101)Phase 3Essential ThrombocythemiaOncologyAug 2029
NCT07269470Ropeginterferon Alfa-2B (P1101)Phase 2Chronic Myeloid LeukemiaOncologyNov 2029

From the company's SEC filings

Complete response letters from FDA

Targets

IFNAR1 (1) IFNAR2 (1)

Companies with the same targets

Diakonos Oncology BriaCell Therapeutics Brii Biosciences Xiamen Amoytop Biotech Biogen AstraZeneca Genrix (Shanghai) Biopharmaceutical

Companies built like this

3D Medicines (Sichuan) Protagonist Therapeutics Greenwich LifeSciences Diakonos Oncology Jiangsu Healthy Life Innovation Medical Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.